Ionis Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on the stock and has a $63.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason Gerberry has given his Buy rating due to a combination of factors including Ionis Pharmaceuticals’ strong second-quarter performance and promising future prospects. The company reported a significant sales beat for its new drug, olezarsen (Tryngolza), particularly in the FCS launch, which exceeded expectations by a wide margin. Additionally, Ionis provided optimistic guidance for future product sales and offered encouraging commentary on upcoming clinical readouts, particularly the Phase 3 sHTG study expected in September.
Gerberry is also optimistic about Ionis’ potential to achieve its first blockbuster drug status in the U.S. if the upcoming CORE/2 readouts are positive. The expectation is that olezarsen will demonstrate a substantial reduction in triglyceride levels and show a positive trend in addressing acute pancreatitis, which are key indicators for clinical success. Furthermore, the company’s pipeline updates and reaffirmation of timelines for key readouts add to the positive outlook, supporting the Buy rating as Ionis approaches several significant catalysts in 2025 and 2026.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $77.00 price target.
IONS’s price has also changed moderately for the past six months – from $33.320 to $43.370, which is a 30.16% increase.